Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
CAMBRIDGE, Mass. and EXTON, Pa., March 12, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company focused on the discovery, development and...
-
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 23, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
-
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 19, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced the closing of its previously announced...
-
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 13, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced the pricing of an underwritten public offering...
-
CAMBRIDGE, Mass. and EXTON, Pa., Feb. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA) ("Idera" or the "Company") today announced that it intends to offer and sell up to...
-
CAMBRIDGE, Mass. and EXTON, Pa., Jan. 26, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing immune-modulating and gene silencing...
-
CAMBRIDGE, Mass. and EXTON, Pa., Jan. 9, 2015 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing toll-like receptor and RNA...
-
- FDA grants Orphan Drug Designation for IMO-8400 for the treatment of Waldenström's macroglobulinemia - Four-week safety review by Data Review Committee for second dose cohort completed in...
-
CAMBRIDGE, Mass., Dec. 15, 2014 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq:IDRA), a clinical-stage biopharmaceutical company developing nucleic acid therapeutics for cancers and rare...
-
- Clinical safety data for IMO-8400 support dose escalation in ongoing Phase 1/2 trials - Preclinical data show promise of early-line combination therapy with IMO-8400 and rituximab CAMBRIDGE,...